Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$5.03 USD
+0.17 (3.50%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $5.02 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Humacyte, Inc. (HUMA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.14 | $25.00 | $6.00 | 149.79% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Humacyte, Inc. comes to $12.14. The forecasts range from a low of $6.00 to a high of $25.00. The average price target represents an increase of 149.79% from the last closing price of $4.86.
Analyst Price Targets (7 )
Broker Rating
Humacyte, Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/18/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
10/10/2024 | The Benchmark Company | Bruce D Jackson | Strong Buy | Strong Buy |
9/9/2024 | EF Hutton Financial | Jason Kolbert | Not Available | Strong Buy |
8/12/2024 | Piper Sandler | Allison M Bratzel | Hold | Hold |
8/12/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
7/2/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
4/1/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $12.14 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 87 of 252 |
Current Quarter EPS Est: | -0.25 |
HUMA FAQs
Humacyte, Inc. (HUMA) currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Humacyte, Inc. (HUMA) is $12.14. The current on short-term price targets is based on 4 reports.
The forecasts for Humacyte, Inc. (HUMA) range from a low of $6 to a high of $25. The average price target represents a increase of $141.35 from the last closing price of $5.03.
The current UPSIDE for Humacyte, Inc. (HUMA) is 141.35%
Based on short-term price targets offered by seven analysts, the average price target for Humacyte, Inc. comes to $12.14. The forecasts range from a low of $6.00 to a high of $25.00. The average price target represents an increase of 149.79% from the last closing price of $4.86.